Related Experiment Video
Updated: Jun 23, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Radiotherapy and targeted therapies in head and neck carcinomas and NSCLC]
1Département de radiothérapie, institut Gustave-Roussy, 94800 Villejuif, France. abruna@oncorad.courlancy.fr
Abstract:
Targeted therapies are at this moment the subject of an intensive research program in head and neck carcinomas and in NSCLC. Their combination with radiotherapy is promising. The studied targets are mostly the EGF receptor and the angiogenesis, with drugs such as cetuximab or bevacizumab. The first clinical results are now available, mostly in head and neck carcinomas. The radiosensitivity is increased, resulting in better survival results, however with a good tolerance profile. Numbers of clinical trials are active now to confirm these results. Particularly, their addition to the reference treatments that are chemo-radiotherapy is studied. The first clinical results will be detailed, as well as their biological explanation.
Insights
Targeted therapies combined with radiotherapy show promise for head and neck cancers and non-small cell lung cancer (NSCLC). Early results indicate improved survival with good tolerance, warranting further clinical trials.
Area of Science:
- Oncology
- Radiotherapy research
Background:
- Targeted therapies are under intensive investigation for head and neck carcinomas and non-small cell lung cancer (NSCLC).
- Combination of targeted therapies with radiotherapy presents a promising treatment strategy.
Purpose of the Study:
- To review the current research and clinical results of targeted therapies in head and neck carcinomas and NSCLC.
- To evaluate the efficacy and safety of combining targeted therapies with radiotherapy.
Main Methods:
- Review of available clinical trial data and published results.
- Focus on targeted therapies such as cetuximab (targeting EGF receptor) and bevacizumab (targeting angiogenesis).
Main Results:
- Initial clinical results, primarily from head and neck carcinomas, show increased radiosensitivity.
- Improved survival outcomes observed with a favorable tolerance profile.
- Ongoing clinical trials are investigating combinations with standard chemo-radiotherapy.
Conclusions:
- Combination of targeted therapies with radiotherapy is a promising approach for head and neck carcinomas and NSCLC.
- Further clinical trials are necessary to confirm these encouraging results and optimize treatment protocols.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

